close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

2.140 +0.050 (+2.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Participate at Upcoming November Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Completes Surface Oncology Acquisition
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Participate at Upcoming September Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting 
From Surface Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Acquire Surface Oncology
From Surface Oncology, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
List price of $995 per carton for two 40 mg/0.8 mL autoinjectors 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Prices Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Proposed Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today